BeiGene Ltd (FRA:49BA)
€ 152 5 (3.4%) Market Cap: 15.89 Bil Enterprise Value: 14.28 Bil PE Ratio: 0 PB Ratio: 5.18 GF Score: 69/100

Beigene Ltd at Cowen Health Care Conference (Virtual) Transcript

Mar 07, 2022 / 02:50PM GMT
Release Date Price: €157 (-0.63%)
Yaron Benjamin Werber
Cowen and Company, LLC, Research Division - MD & Senior Biotechnology Analyst

And good morning, everybody, or good afternoon or even good evening in this case. Thank you once again for joining us for the 42nd Annual Cowen Healthcare Conference. I'm Yaron Werber, biotech analyst, and it's a great pleasure to moderate the next fireside chat with BeiGene. Today, we have with us John Oyler, who is the CEO; Julia Wang, who is the CFO; Lai Wang, who is the Global Head of R&D; and Kevin Mannix as well, who's VP of IR. So ladies and gentlemen, thanks for joining us. Always good to see you.

John V. Oyler
BeiGene, Ltd. - Co-Founder, Executive Chairman & CEO

Thank you. Pleasure to be here.

Questions & Answers

Yaron Benjamin Werber
Cowen and Company, LLC, Research Division - MD & Senior Biotechnology Analyst

So we have a half hour and BeiGene is becoming obviously a fairly big company with a huge pipeline and now 2 or actually 3 marketed products that you got approved and then

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot